Clinical Trial Update: A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluates trabectedin (ET-743) in patients with advanced breast cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ET-743 (Trabectedin) (trabectedin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Breast Neoplasms, Neoplasms | Phase 2 | Status: COMPLETED